Dulaglutide research: studies, doses and safety

A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.

Also called: Trulicity, LY2189265.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

117 registered interventional records found before the cutoff, including planned trials and comparator arms. Selected major reports appear below; this is not a completed-trial count.

Key studies

  • EGO: early weekly dose steps: 0.5→1 mg −1.38%; 1 mg −1.32%; 1→2 mg −1.59%; placebo −0.24%. (source)
  • Early weekly monotherapy: 0.5/1/1.5 mg: −0.9/−1.0/−1.0%; placebo 0.0%. The abstract does not give the 0.1 mg HbA1c result. (source)
  • AWARD-5: seven-dose selection: 1.5 mg was selected as optimal; 0.75 mg was the second selected dose. (source)
  • Higher doses: 1.5, 3 and 4.5 mg: 1.5/3/4.5 mg: −1.23/−1.31/−1.40%; placebo −0.44%. (source)
  • AWARD-1: metformin plus pioglitazone: 1.5 mg −1.51%; 0.75 mg −1.30%; exenatide −0.99%; placebo −0.46%. (source)
  • AWARD-2: versus basal insulin: 1.5 mg −1.08%; 0.75 mg −0.76%; glargine −0.63%. (source)

Related to Dulaglutide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.